SARomics Biostructures provides premium protein crystallization, protein crystallography and drug discovery services.
SARomics Biostructures is based in Lund, Sweden, conveniently located in the heart of Medicon Valley, one of Europe's strongest biotech clusters. Their labs and offices are located at Medicon Village, a new research center created at the former Astra Zeneca site in Lund. The company was founded in 2006 and quickly established itself as the No. 1 provider of protein 3D structure determination and structure-based drug discovery services in Scandinavia. Currently the company provides premium structural biology services worldwide.
Dr. Björn Walse, co-founder and Chief Executive Officer of SARomics Biostructures AB has over 15 years of drug discovery and research management experience from the biotech industry. Prior to establishing SARomics Biostructures Dr. Walse served as head of structural chemistry at Active Biotech AB, where he was responsible for build-up and running of the structural chemistry platform. At Active Biotech he also participated in the molecular design of a biopharmaceutical therapeutics currently in phase III trials for an oncology indication. Prior to this, Dr. Walse performed postdoctoral research at UC Berkeley. Dr. Walse received his Doctorate in physical chemistry from Lund University and his M.Sc. in Chemical Engineering from Lund Institute of Technology.
Dr. Derek Logan is the co-founder and CSO of Saromics Biostructures. He has extensive international research experience from the Universities of Oxford, Strasbourg (IGBMC) and Stockholm (Molecular Biology & Biochemistry). He has held a prestigious scholarship from the Carnegie Trust for the Universities of Scotland. Current academic research includes the use of hybrid structural methods (X-ray crystallography, small angle X-ray scattering, neutron diffraction and cryo-electron microscopy) to understand structure-function relationships at multiple levels of organisation and detail, as well as development of facilities for structural biology at the new synchrotron MAX-IV.